PortfoliosLab logoPortfoliosLab logo
PARA vs. PFE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PARA vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Paramount Global Class B (PARA) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


PARA

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

PFE

1D
-1.44%
1M
-4.56%
YTD
2.61%
6M
2.69%
1Y
10.06%
3Y*
-8.03%
5Y*
-4.01%
10Y*
1.82%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PARA vs. PFE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PARA
Paramount Global Class B
0.00%6.45%-27.96%-10.43%-41.80%-17.17%-7.58%-2.34%-24.86%-6.17%
PFE
Pfizer Inc.
2.61%0.65%-2.22%-41.26%-10.41%66.70%3.07%-6.91%24.82%15.90%

Correlation

The correlation between PARA and PFE is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.16

Correlation (10Y)
Calculated over the trailing 10-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Jan 3, 2006

0.30

Over the past year, the correlation between PARA and PFE has dropped to 0.09 - well below their long-term average of 0.30, suggesting their price drivers have been diverging.

Fundamentals

Market Cap

PARA:

$12.23B

PFE:

$141.67B

EPS

PARA:

-$0.65

PFE:

$1.31

PS Ratio

PARA:

0.37

PFE:

2.23

PB Ratio

PARA:

1.05

PFE:

1.57

Total Revenue (TTM)

PARA:

$28.89B

PFE:

$63.32B

Gross Profit (TTM)

PARA:

$8.54B

PFE:

$43.91B

EBITDA (TTM)

PARA:

$2.64B

PFE:

$16.94B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PARA vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PARA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


PFE
PFE Risk / Return Rank: 5656
Overall Rank
PFE Sharpe Ratio Rank: 5757
Sharpe Ratio Rank
PFE Sortino Ratio Rank: 5151
Sortino Ratio Rank
PFE Omega Ratio Rank: 4949
Omega Ratio Rank
PFE Calmar Ratio Rank: 6161
Calmar Ratio Rank
PFE Martin Ratio Rank: 6060
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PARA vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Paramount Global Class B (PARA) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PARAPFEDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.10

Calmar ratioReturn relative to maximum drawdown

0.84

Martin ratioReturn relative to average drawdown

1.72

PARA vs. PFE - Sharpe Ratio Comparison


Loading charts...

Drawdowns

PARA vs. PFE - Drawdown Comparison


Loading charts...

Drawdown Indicators


PARAPFEDifference

Max Drawdown

Largest peak-to-trough decline

-69.24%

Max Drawdown (1Y)

Largest decline over 1 year

-11.99%

Max Drawdown (3Y)

Largest decline over 3 years

-37.69%

Max Drawdown (5Y)

Largest decline over 5 years

-58.96%

Max Drawdown (10Y)

Largest decline over 10 years

-58.96%

Current Drawdown

Current decline from peak

-48.77%

Average Drawdown

Average peak-to-trough decline

-22.91%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.85%

Volatility

PARA vs. PFE - Volatility Comparison


Loading charts...

Volatility by Period


PARAPFEDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.49%

Volatility (6M)

Calculated over the trailing 6-month period

14.28%

Volatility (1Y)

Calculated over the trailing 1-year period

23.93%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.50%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.91%

Dividends

PARA vs. PFE - Dividend Comparison

PARA has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.96%.


PositionTTM20252024202320222021202020192018201720162015
PARA
Paramount Global Class B
0.00%0.91%1.91%2.64%5.69%3.18%2.58%1.86%1.65%1.22%1.04%1.27%
PFE
Pfizer Inc.
6.96%6.91%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.53%3.69%3.47%

Financials

PARA vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between Paramount Global Class B and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B15.00B20.00B25.00B20222023202420252026
8.15B
14.45B
(PARA) Total Revenue
(PFE) Total Revenue
Values in USD except per share items

PARA vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between Paramount Global Class B and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

10.0%20.0%30.0%40.0%50.0%60.0%70.0%20222023202420252026
24.3%
67.3%
Portfolio components
PARA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Paramount Global Class B reported a gross profit of 1.98B and revenue of 8.15B. Therefore, the gross margin over that period was 24.3%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.

PARA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Paramount Global Class B reported an operating income of 207.00M and revenue of 8.15B, resulting in an operating margin of 2.5%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.

PARA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Paramount Global Class B reported a net income of -573.00M and revenue of 8.15B, resulting in a net margin of -7.0%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.


Frequently Asked Questions


PARA and PFE have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for PARA and PFE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer